Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05458479 · ClinicalTrials.gov registry record · Phase 4
Fluoxetine Treatment of Depression in Down Syndrome
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT05458479: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT05458479 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05458479, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of the study is to do a preliminary assessment of whether fluoxetine is effective, safe, and tolerable for the treatment of depression in adults with Down syndrome.
Interventions
- DRUG Fluoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-12-05 |
| Est. Completion | 2024-02-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05458479
The ClinicalTrials.gov registry entry for NCT05458479 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fluoxetine is the first listed.
NCT05458479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05458479 about?
NCT05458479 is a clinical study titled "Fluoxetine Treatment of Depression in Down Syndrome". The purpose of the study is to do a preliminary assessment of whether fluoxetine is effective, safe, and tolerable for the treatment of depression in adults with Down syndrome.
What is the current status of trial NCT05458479?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2022-12-05. Estimated completion is 2024-02-26.
What interventions are being tested in trial NCT05458479?
The interventions under investigation include: Fluoxetine (DRUG).
Who is sponsoring clinical trial NCT05458479?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.